Improving Blood Pressure in High-Risk Patients With CKD Using an Interdisciplinary Remote Hypertension Program

Related Experiment Video

Updated: May 9, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K

Molly C Fisher1, Sharon Rikin2, Sonali Gupta1

  • 1Division of Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, New York, USA.

Kidney International Reports
|April 30, 2025
PubMed

Insights

This study shows that remote patient monitoring (RPM) effectively improves blood pressure (BP) control in Black and Hispanic patients with chronic kidney disease (CKD). The program demonstrated high feasibility and significant BP reductions, offering a promising approach to reduce health disparities.

Area of Science:

  • Nephrology
  • Cardiology
  • Health Equity

Background:

  • Racial and ethnic disparities persist in achieving blood pressure (BP) control among patients with chronic kidney disease (CKD).
  • Interventions are needed to address these disparities and improve hypertension management in vulnerable populations.
  • Remote patient monitoring (RPM) offers a potential solution for enhanced BP management in CKD patients.

Purpose of the Study:

  • To determine the feasibility and effectiveness of an interdisciplinary RPM hypertension program.
  • To evaluate the program's impact on BP control in predominantly Black and Hispanic patients with CKD.
  • To assess the potential of RPM in reducing racial and ethnic disparities in hypertension management.

Main Methods:

  • An RPM hypertension program was evaluated in a New York City health system (July 2021-October 2022).
  • Patients used cellular-enabled BP devices for real-time data transmission, receiving lifestyle education and telemedicine-based medication adjustments by a nurse practitioner.
  • Feasibility was assessed by enrollment, participation, and retention rates; BP control was measured by mean BP change at 3 months and the proportion achieving BP < 130/80 mmHg at 6 months.

Main Results:

  • The program demonstrated high feasibility, with 91.9% enrollment and 78.4% retention at 3 months among invited patients.
  • Significant mean reductions in systolic BP (-15.0 mmHg) and diastolic BP (-6.7 mmHg) were observed at 3 months (P < 0.0001 and P = 0.0007, respectively).
  • By 6 months, 49.4% of participants achieved the target BP of < 130/80 mmHg.

Conclusions:

  • The interdisciplinary RPM hypertension program was feasible and effective in improving BP control in CKD patients.
  • This approach shows promise for increasing equity in hypertension management, particularly for racial and ethnic minority groups.
  • Further research is needed to evaluate the long-term maintenance of BP control with RPM compared to usual care.
Abstract

Keywords:
CKDhealth equityhypertensioninterdisciplinarytelemedicine

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.4K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
439
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
398
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277